Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD Corp. To Invest $300 Mil. In Safety-Engineered Protection Devices

This article was originally published in The Gray Sheet

Executive Summary

BD Corp. says it will invest $300 mil. in its Advanced Protection Technologies line of safety-engineered protection devices during fiscal year 2001.

You may also be interested in...



BD To Achieve Safety Products Sales Target Early Aided By OSHA Revision

The Needlestick Safety and Prevention Act and subsequent revision to the Occupational Safety and Health Administration's bloodborne pathogens standard will help BD Corp. reach the $800 mil. sales mark by the end of 2003, the firm is now projecting, well ahead of its earlier forecast of 2005.

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel